Dr. Lindsey Murray will lead C-Path’s New Rare Disease COA ConsortiumContinue reading
Author Archives: Roxan Olivas
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium
The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseasesContinue reading
C-Path’s ePRO Consortium Announces Rebranding, Changes Name to eCOA Consortium
TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Reported Outcome (ePRO) Consortium is now the Electronic Clinical Outcome Assessment (eCOA) Consortium. This rebranding more accurately reflects the expanded portfolio range of work performed by the consortium, the actual capabilities of member firms and the scope and significance of the consortium’s role. The new name was chosen to more authentically characterize the mission and aims of the consortium, which have evolved significantly since its inception in 2011.Continue reading
C-Path and NICHD to Share Real-world Data to Advance Neonatal Drug Development
TUCSON, Ariz., Dec. 1, 2021 — Critical Path Institute’s (C-Path) International Neonatal Consortium (INC) today announced a seminal data-sharing collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health, as a part of a U.S. Food and Drug Administration (FDA) sponsored project to generate actionable real-world evidence (RWE) for neonatal drug development from real-world neonatal data (RWD).Continue reading
C-Path Joins New Coalition to Improve Patient Care and Address Unmet Medical Needs through Community-Level Clinical Trials
Tools being developed by C-Path’s CURE Drug Repurposing Collaboratory will help incorporate adaptive platform trial protocols in clinical practice.Continue reading
C-Path and Cure Mito Announce Data Sharing Agreement to Support Treatment Development For Leigh Syndrome and Mitochondrial Disease
TUCSON, Ariz., November 9, 2021 — Critical Path Institute (C-Path) and Cure Mito Foundation (Cure Mito) today announced a joint collaboration to significantly promote data sharing and accelerate Leigh syndrome and other rare mitochondrial disease data incorporation into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading
Academic Innovation Leader and Experienced Scientist to Join C-Path’s PKD Consortium
Sorin Fedeles, Ph.D., MBA to serve as new Executive Director
TUCSON, Ariz., October 14, 2021 – Critical Path Institute (C-Path) today announced it has named Sorin Fedeles, Ph.D., MBA as Executive Director of its Polycystic Kidney Disease Outcomes Consortium (PKDOC), effective October 1, 2021.Continue reading
C-Path Appoints Tufts’ Jonathan M. Davis as Senior Advisor in Pediatrics
TUCSON, Ariz., September 16, 2021 — Critical Path Institute (C-Path) today announced the appointment of Jonathan M. Davis, M.D., as Senior Advisor in Pediatrics working with its International Neonatal Consortium (INC) and advising on drug and device development in infants and children, effective immediately.Continue reading
Rare Disease Innovation and Data Sharing Accelerated by New RDCA-DAP Program
C-Path, NORD and FDA host annual meeting, demonstration and launch of new rare disease data and analytics platform.Continue reading
C-Path and RARE-X Establish New Collaboration for Rare Disease Data Sharing
RARE-X and Critical Path Institute align on their mission and commitment for data sharing to improve rare disease research
TUCSON, Ariz. and ALISO VIEJO, Calif., September 13, 2021 — Critical Path Institute (C-Path), who’s aim is to catalyze the development of new approaches that advance medical innovation and regulatory science, today announced a collaboration with RARE-X to improve ways researchers can access and analyze patient data. RARE-X is a nonprofit organization dedicated to enabling patient communities to collect, manage and share their de-identified data to advance research.Continue reading